Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 10/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SCN1A | P35498 | 2/20 | 0.61 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.61 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.61 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698441 | 1.00 | SCN4A (0.61) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| SCHEMBL7701174 | 1.00 | SCN4A (0.61) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| Hydrochloric Acid SCHEMBL11657872 | 0.98 | LMNA (0.62) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| SCHEMBL11661140 | 0.90 | NR3C1 (0.57) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| Maleic Acid SCHEMBL11662225 | 0.86 | HTR1D (0.48) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| SCHEMBL13884448 | 0.85 | SCN4A (0.61) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| SCHEMBL5684024 | 0.81 | SCN4A (0.58) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| SCHEMBL8816903 | 0.81 | SCN4A (0.58) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| SCHEMBL8815305 | 0.81 | SCN4A (0.58) | SCN4ACYP2D6LMNASCN1ASCN5A | |
| Hydrochloric Acid SCHEMBL8816944 | 0.80 | LMNA (0.59) | SCN4ACYP2D6LMNASCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019201432-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2019202052-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| EP-3494105-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | Human Biomolecular Research Institute (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3342779-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-1037871-B1 | NOVEL ANTIARRHYTHMIC COMPOUNDS | GYOGYSZERKUTATO INTEZET (HU) | 2002-07-03 | — | — | EP | disclosed |
| US-6265445-B1 | CARDIOVASCULAR DISORDERS | GYOGYSZERKUTATO INTEZET KFT (HU) | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | TFPI, F11, F13B | SCN4A 3919/4885CYP2D6 788/4885LMNA 1300/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | SCN4A 4170/4885CYP2D6 933/4885LMNA 2426/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | SCN4A 4170/4885CYP2D6 933/4885LMNA 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.